Cytovia grants Latin American Ceplene rights to Pint Pharma
Executive Summary
Cytovia Inc., the oncology division of Immune Pharmaceuticals Inc., granted Pint Pharma GMBH rights to market and distribute Ceplene (histamine dihydrochloride) for acute myeloid leukemia in Latin America, including Argentina, Brazil, Chile, Colombia, and Mexico.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice